Albert Einstein College of Medicine

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Albert Einstein College of Medicine sits in the top decile of US sponsors by registered trial count (#169 of 15,742 sponsors by registered trial count).

175 total trials 20 currently recruiting 121 completed early-phase tilt top decile by trial count

Albert Einstein College of Medicine: 175 sponsored US clinical trials, 20 recruiting.

Albert Einstein College of Medicine sponsors 175 registered US clinical trials on ClinicalTrials.gov, 20 of them currently recruiting, and 121 completed. 17 of these trials are in Phase 3-4 (later-stage) and 49 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Pain, with 5 trials.

Top-decile sponsor footprint

Albert Einstein College of Medicine ranks in the top decile of sponsors by registered trial count (#169 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 44/100

121 of 148 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

175 total, page 4 of 4

COMPLETED Phase 2

Early Insulin and Development of ARDS

NCT00605696

COMPLETED Phase 3

Provider Approaches to Improved Rates of Infant Nutrition and Growth Study

NCT00643253

COMPLETED Phase 2

Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans

NCT01354977

TERMINATED Phase 2

Mechanisms of Hypoglycemia Associated Autonomic Failure

NCT00678145

COMPLETED NA

Boosting Breastfeeding in Low-Income, Multi-ethnic Women: A Primary Care Based RCT

NCT00619632

COMPLETED NA

Exploratory Study Of The ERCC-1 Gene

NCT00846482

COMPLETED Phase 1

Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy

NCT00574587

COMPLETED NA

Directly Observed Hepatitis C Treatment in Methadone Clinics

NCT01442311

COMPLETED

Cardiovascular Disease Risk Factors in Chinese American Immigrants

NCT00362128

COMPLETED NA

Controlling Hypertension in Diabetes- Feasibility Study

NCT01145742

COMPLETED Phase 2

Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer

NCT00950365

COMPLETED Phase 1

Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia

NCT00450944

COMPLETED NA

The RECHARGE Low Carbohydrate Diet Trial for Metastatic Cancer

NCT00444054

COMPLETED NA

Reactive Oxygen Species in the Pathogenesis of Diabetic Complications

NCT00703989

COMPLETED

Validation of the San Francisco Syncope Rule

NCT00300625

COMPLETED NA

Mind-Body Program for Cancer Patients

NCT00179387

COMPLETED

Natural History of Oro-pharyngeal Cancer Precursors

NCT00179361

COMPLETED NA

Diabetes Dietary Study- Low Carbohydrate and Low-Fat Diets in Type 2 Diabetes

NCT00795691

COMPLETED Phase 2

SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia

NCT00075569

COMPLETED

Comparative Pharmacokinetics (PK) Study of Efavirenz or Lopinavir/Ritonavir Between Older and Younger HIV-Infected Adults

NCT00179335

COMPLETED NA

Improving Diabetes Outcomes With Activity, Nutrition and Medication

NCT00179374

COMPLETED NA

Yoga-Based Rehabilitation Program in Reducing Physical and Emotional Side Effects in Patients With Cancer

NCT00179348

COMPLETED Phase 4

The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans

NCT00179400

COMPLETED Phase 1

Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer

NCT00005807

COMPLETED Phase 2

Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy

NCT00004149

← Previous Page 4 of 4

Phase Distribution

PhaseTrial count
Phase 1 20
Phase 2 29
Phase 3 5
Phase 4 12

What is open in the Albert Einstein College of Medicine pipeline

20 recruiting of 175 indexed (11% open); 121 completed (69%).

Phase mix: 17 late (III/IV) vs 49 early (I/II) (early-phase heavy).

Top condition: Chronic Pain (5 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Albert Einstein College of Medicine: open-pipeline peers nationwide

Peers matched on 175 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Albert Einstein College of Medicine sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600800 0%5%10%15%20% Total trials Recruiting share Albert Einstein College of MedicineBausch & Lomb IncorporatedUConn HealthBaylor Research InstituteAbbottUniversity of MemphisChildren's Mercy Hospital Kansas CityJanssen Research & DevelopmentBarbara Ann Karmanos Cancer Institute
Albert Einstein College of Medicine sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Albert Einstein College of Medicine sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 175 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

What to do with this Albert Einstein College of Medicine page

175 registered trials is a research-attention snapshot, not an endorsement of Albert Einstein College of Medicine or any single study.

  • 20 of Albert Einstein College of Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Chronic Pain is the condition Albert Einstein College of Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chronic Pain trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Albert Einstein College of Medicine pipeline card: 175 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.